Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03860597 · ClinicalTrials.gov registry record · Phase 4
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
A Phase 4 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
NCT03860597 is a Phase 4 study that has completed, run by University of California, San Diego. The registered enrollment target is 42 participants.
The verdict
NCT03860597, a Phase 4 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
Study Summary
This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.
Interventions
- DRUG Placebos
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03860597
The ClinicalTrials.gov registry entry for NCT03860597 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03860597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03860597 about?
NCT03860597 is a clinical study titled "Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia". This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.
What is the current status of trial NCT03860597?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2018-04-01. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03860597?
The interventions under investigation include: Placebos (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT03860597?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.